<Disease><Name>G(M2)-GANGLIOSIDOSIS: GM2 ACTIVATOR DEFICIENCY</Name><Synonym>TAY-SACHS DISEASE, AB VARIANT; G(M2)-GANGLIOSIDOSIS WITH HEXOAMINIDASE A DEFICIENCY</Synonym><OMIM><Number>272750</Number><URL>http://omim.org/entry/272750</URL></OMIM><Orphanet><Number>309246</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=309246</URL></Orphanet><Protein><Number>Ganglioside GM2 activator</Number><URL>http://www.uniprot.org/uniprot/P17900</URL></Protein><ExPASy><Number /><URL /></ExPASy><Gene>5q33.1Detail information to gene locus by the National Center for Biotechnology Information NCBI:

GM2 ganglioside activator protein
</Gene><ICD>E75.0</ICD><Summary>very rare ;autosomal recessive ;mutation in the GM2A gene;infantile acute form, indistinguishable from infantile Tay-Sachs or Sandhoff disease</Summary><Symptoms><symtomp><id>2211</id><symptom>blindness, visual loss, visual impairment</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1733</id><symptom>cherry-red spot on retinal macula</symptom><category>EYES</category></symtomp><symtomp><id>2423</id><symptom>early death</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2160</id><symptom>EEG abnormalities [-]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1896</id><symptom>hypertonia, spasticity</symptom><category>MUSCLES</category></symtomp><symtomp><id>1897</id><symptom>hypotonia</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1953</id><symptom>lethargy, drowsiness, apathy</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1887</id><symptom>macrocephaly (large calvaria, &gt;2 SD for age)</symptom><category>HEAD</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1919</id><symptom>progressive neurologic defect</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>3479</id><symptom>speech difficulties</symptom><category>LUNG OR RESPIRATORY SYSTEM | NERVOUS SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>72</id><name>L-Pyroglutamic acid (5-Oxoproline)</name><specimen>urine</specimen><value>increased</value><min>42.00</min><max>115.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>560</id><name>L-Pyroglutamic acid (5-Oxoproline)</name><specimen>urine</specimen><value>increased</value><min>3.00</min><max>54.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>563</id><name>L-Pyroglutamic acid (5-Oxoproline)</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>all</age><method /><comment /></metabolite><metabolite><id>1168</id><name>L-Pyroglutamic acid (5-Oxoproline)</name><specimen>urine</specimen><value>increased</value><min>77.00</min><max>133.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1284</id><name>L-Pyroglutamic acid (5-Oxoproline)</name><specimen>blood</specimen><value>increased</value><min>14.00</min><max>62.54</max><unit>&#181;mol/ml</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1285</id><name>L-Pyroglutamic acid (5-Oxoproline)</name><specimen>serum</specimen><value>increased</value><min>23.80</min><max>106.32</max><unit>&#181;mol/ml</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1977</id><name>L-Pyroglutamic acid (5-Oxoproline)</name><specimen>urine</specimen><value>increased</value><min>10.20</min><max>32.60</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>394</id><name>L-Pyroglutamic acid (5-Oxoproline)</name><specimen>plasma</specimen><value>increased</value><min>13.00</min><max>161.00</max><unit>&#181;mol/l</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>559</id><name>L-Pyroglutamic acid (5-Oxoproline)</name><specimen>urine</specimen><value>increased</value><min>5.00</min><max>44.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>965</id><name>Oligosaccharides</name><specimen>urine</specimen><value>increased</value><min>    </min><max>    </max><unit>not detectable</unit><age>no data</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>4503</id><title>The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy</title><author>Regier DS,</author><journal>Pediatr Endocrinol Rev Suppl</journal><year>2016</year><book /><volume>13</volume><number>1</number><pages>663-673</pages><co_aut>et al.</co_aut></literature><literature><id>4505</id><title>Ashkenazi Jewish population screening for Tay-Sachs disease: the international and Australian experience</title><author>Lew RM,</author><journal>J Paediatr Child Health</journal><year>2015</year><book /><volume>51</volume><number>3</number><pages>271-279</pages><co_aut>et al.</co_aut></literature><literature><id>4506</id><title>Tay-Sachs disease: current perspectives from Australia</title><author>Lew RM,</author><journal>Appl Clin Genet</journal><year>2015</year><book /><volume>8</volume><number>0</number><pages>19-25</pages><co_aut>et al.</co_aut></literature><literature><id>4507</id><title>Tay-Sachs disease screening and counseling families at risk for metabolic disease</title><author>Sutton VR</author><journal>Obstet Gynecol Clin North Am</journal><year>2002</year><book /><volume>29</volume><number>2</number><pages>287-296</pages><co_aut /></literature><literature><id>1003</id><title>5-Oxoprolinuria in patients with and without defects in the gamma-glutamyl cycle</title><author>Mayatepek E</author><journal>Eur J Pediatr</journal><year>1999</year><book /><volume>158</volume><number>0</number><pages>221-225</pages><co_aut /></literature><literature><id>156</id><title>The GM2 gangliosidoses</title><author>Gravel RA</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>92</number><pages>2839-2879</pages><co_aut>Clarke JTR, Kaback MM, Mahuran D, Sandhoff K, Suzuki K</co_aut></literature></Literatures></Disease>